{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:59:08Z","timestamp":1791874748527,"version":"4.3.4"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Zanubrutinib (Brukinsa) is a next-generation Bruton\u2019s tyrosine kinase inhibitor approved for the treatment of relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, a comprehensive quantitative assessment of its safety profile remains limited. Methods: A systematic search of PubMed, Scopus, Web of Science, and MEDLINE was conducted to identify clinical trials published up to August 2025 that reported treatment-emergent adverse events (TEAEs) associated with zanubrutinib in patients with R\/R CLL\/SLL. Pooled incidence estimates were calculated using a random-effects model (DerSimonian and Laird method). Results: Four studies comprising 508 patients were included, with median follow-up durations ranging from 15.1 to 34.5 months. The pooled incidence of any-grade adverse events was 98.5% (95% CI, 97.1\u201399.9), while grade \u22653 adverse events occurred in 67.0% (95% CI, 55.4\u201378.7). Serious adverse events were reported in 32.2% of patients (95% CI, 25.1\u201339.3), treatment discontinuation due to toxicity occurred in 7.2% (95% CI, 2.5\u201311.8), and adverse event-related mortality was observed in 7.1% (95% CI, 0.2\u201313.9). The most frequently reported hematological adverse events were neutropenia (32.1%) and anemia (26.7%), while common non-hematological adverse events included bleeding events (51.9%), upper respiratory tract infections (27.2%), pneumonia (19.4%), and hypertension (16.4%). Atrial fibrillation occurred in 2.9% of patients. Conclusions: Zanubrutinib was associated with a high incidence of adverse events, although rates of treatment discontinuation and atrial fibrillation were relatively low, supporting its tolerability in R\/R CLL\/SLL within clinical trial settings while highlighting the need for continued long-term and real-world safety monitoring.<\/jats:p>","DOI":"10.3390\/ph19030467","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:12:24Z","timestamp":1773321144000},"page":"467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is Brukinsa (Zanubrutinib) a Safer Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-7304","authenticated-orcid":false,"given":"Helal F.","family":"Hetta","sequence":"first","affiliation":[{"name":"Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7946-4477","authenticated-orcid":false,"given":"Ayman","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki A.","family":"Aljuaid","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan T.","family":"Mojmami","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyadh S.","family":"Alotibi","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Alqabaly","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf A.","family":"Aldosari","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami A.","family":"Alshahri","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid I. A.","family":"Asiri","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed S.","family":"Alamri","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez A.","family":"Alanazi","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek S. A.","family":"Alenazi","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Albuhayri","sequence":"additional","affiliation":[{"name":"PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7374-9334","authenticated-orcid":false,"given":"Yasmin N.","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-2714","authenticated-orcid":false,"given":"Reem","family":"Sayad","sequence":"additional","affiliation":[{"name":"Department of Histology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: A review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.COT.0000532458.17691.98","article-title":"Acalabrutinib (Calquence\u00ae)","volume":"40","author":"Finnes","year":"2018","journal-title":"Oncol. Times"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e011040","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: A machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Reimbursement Team (2022). Zanubrutinib (Brukinsa). Can. J. Health Technol., 2.","DOI":"10.51731\/cjht.2022.253"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Alatawi, Y., Alanazi, F.E., Alattar, A., Alshaman, R., Ramadan, Y.N., Sayad, R., and Hetta, H.F. (2025). Therapeutic Impact of Zanubrutinib in Chronic Lymphocytic Leukemia: Evidence from a Systematic Review and Single-Arm Meta-Analysis. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111674"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Higgins, J. (2008). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Collaboration John Wiley Sons Ltd.","DOI":"10.1002\/9780470712184"},{"key":"ref_16","first-page":"90","article-title":"Using the common terminology criteria for adverse events (CTCAE\u2013version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dhandia, D., Jain, S., Shukla, V.K., Sharma, N., Yadav, P., and Arora, S. (2025). International Council for Harmonization: Reception to Implementation. Understanding Pharmaceutical Standards and Regulations, Routledge.","DOI":"10.4324\/9781003500971-15"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"key":"ref_19","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-025-03925-1","article-title":"Zanubrutinib in Japanese treatment-naive and relapsed\/refractory patients with Waldenstrom macroglobulinemia and CLL\/SLL","volume":"121","author":"Izutsu","year":"2025","journal-title":"Int. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/bloodadvances.2024015493","article-title":"Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: Updated results","volume":"9","author":"Shadman","year":"2025","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_24","first-page":"2031","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40256-025-00757-6","article-title":"Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents","volume":"26","author":"Spadafora","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Molica, S., Tam, C., Allsup, D., and Polliack, A. (2023). Advancements in the treatment of CLL: The rise of zanubrutinib as a preferred therapeutic option. Cancers, 15.","DOI":"10.3390\/cancers15143737"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:42:13Z","timestamp":1773322933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030467"],"URL":"https:\/\/doi.org\/10.3390\/ph19030467","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}